Metastatic Clear Cell Renal Cell Carcinoma Clinical Trial
Official title:
Comparison of [18F] PSMA-1007 PET/CT and Conventional Imaging in the Detection of Metastatic Clear Cell Renal Cell Carcinoma
Staging of kidney cancer is primarily achieved by computerized tomography (CT) scans or magnetic resonance imaging (MRI). If a patient is found to have limited metastatic disease, surgical removal or radiation therapy could be considered in order to control the majority of the disease. However, if metastases are more widespread, systemic (drug) therapy may be the preferred management option. The identification of additional metastatic sites using more sensitive imaging modalities therefore has the potential to alter management, and this remains an unmet need in the field. This study will investigate the utility of positron emission tomography (PET) imaging with PSMA (prostate specific membrane antigen). Kidney cancer of the clear cell subtype has demonstrated high expression of PSMA, making it a disease in which PSMA-targeted PET imaging could help to identify occult metastatic disease.
This will be a single-institution prospective, open-label feasibility study involving patients ≥18 years of age with metastatic clear cell RCC who have not yet received systemic therapy. Patients with evidence of metastatic disease on conventional imaging will require histologic confirmation by biopsy. At our institution, approximately 30 new metastatic clear cell RCC (mRCC) patients are seen each year, and a previous analysis reported that 92% of 10,105 patients with mRCC in the International mRCC Database Consortium (IMDC) database were found to have clear cell histology; therefore, difficulty with recruitment into this study over a period of 2 years is not anticipated. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01510119 -
Autophagy Inhibition to Augment Mammilian Target of Rapamycin (mTOR) Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine (HCQ) in Patients With Previously Treated Renal Cell Carcinoma
|
Phase 1/Phase 2 | |
| Completed |
NCT01896271 -
High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer
|
Phase 2 | |
| Recruiting |
NCT06059014 -
Phase I/II Study Evaluating PSMA Targeted Radionuclide Therapy in Adult Patients With Metastatic Clear Cell Renal Cancer
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05122546 -
CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT04904302 -
Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer
|
Phase 2 | |
| Recruiting |
NCT04510597 -
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
|
Phase 3 | |
| Terminated |
NCT02781506 -
Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell Renal Cell Carcinoma
|
Phase 2 | |
| Recruiting |
NCT06399419 -
CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT06361810 -
PSMA Therapy and Immunotherapy in Kidney Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04370509 -
Pembrolizumab With or Without Axitinib for Treatment of Locally Advanced or Metastatic Clear Cell Kidney Cancer in Patients Undergoing Surgery
|
Phase 2 | |
| Recruiting |
NCT05012371 -
Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer
|
Phase 2 | |
| Terminated |
NCT03334409 -
Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery
|
Phase 2 | |
| Completed |
NCT02848768 -
Validation of a Predictive Nomogram of Response or Resistance to Targeted Therapies in Metastatic Clear Cell Renal Cell Carcinoma
|
N/A | |
| Recruiting |
NCT05361720 -
Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study
|
Phase 2 | |
| Terminated |
NCT03260504 -
Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer
|
Phase 1 | |
| Terminated |
NCT01391130 -
A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma
|
Phase 2 | |
| Completed |
NCT02002312 -
Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer
|
Phase 2 | |
| Recruiting |
NCT04388852 -
DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers
|
Phase 1 | |
| Recruiting |
NCT05879471 -
68Ga-NY104 PET/CT in Patients With Metastatic Clear Cell Renal Cell Carcinoma
|
Phase 2 | |
| Recruiting |
NCT06349642 -
Predicting Response to Immune Checkpoint Inhibitors Across Solid Tumors Using a Live Tumor Diagnostic Platform
|